Blend identity and evidence limits
BPC-157 + TB-500 Blend
Why a commercial blend cannot be treated as equivalent to the small BPC-157 and thymosin beta-4 study.
Source and review status
Identity unresolved
Identity search checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 December 2026.
The identity distinction
The catalogue name describes a proposed BPC-157 and TB-500 combination but does not identify a verified finished formulation. FDA’s reference uses TB-500 for the LKKTETQ fragment of thymosin beta-4. A paper referring to TB4 does not automatically establish that it tested the same material.
Sources: U.S. Food and Drug Administration
The often-cited knee report
A 2021 retrospective report reached 16 patients by telephone; only four had received BPC-157 with TB4. There was no control group, and the report did not use standard measures of function or quality of life. It cannot establish a benefit of the combination, distinguish treatment from other causes of improvement, or validate a product sold as this blend.
Sources: Lee and Padgett, Alternative Therapies in Health and Medicine; indexed by PubMed
What remains unresolved
The actual ingredient identities, ratio, stability and finished-product safety remain unverified. FDA identifies insufficient safety information for BPC-157 and the TB-500 fragment, alongside peptide impurity and immune-response concerns. Combining names does not resolve those gaps.
Sources: U.S. Food and Drug Administration
Published sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
U.S. Food and Drug Administration. Current FDA reference; accessed 6 September 2026.
Supports: Named substance and route-specific safety findings. Ingredient assessments do not validate a finished blend.
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Lee and Padgett, Alternative Therapies in Health and Medicine; indexed by PubMed. Published July 2021; accessed 6 September 2026.
Supports: Small retrospective report with 16 respondents, including four who received BPC-157 with TB4. Does not establish efficacy or identify a commercial TB-500 mixture.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Identity and evidence limits documented | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.